{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-014099","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.523092+00:00","generated_at":"2026-05-26T19:37:56.493360+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Sagimet files updated investor presentation; no specific material changes disclosed","bullets":["Filed an updated slide presentation dated February 14, 2025, for use in investor meetings.","Presentation title: 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne & Cancer'.","No financial results, guidance changes, or material events are reported in the filing or exhibit excerpt.","The 8-K is a routine update under Item 8.01 with no detailed new information provided.","Confidence is low because the full presentation slides are not visible in the filing text."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-014099","json":"https://secwatch.observer/filing/0001104659-25-014099.json","markdown":"https://secwatch.observer/filing/0001104659-25-014099.md","text":"https://secwatch.observer/filing/0001104659-25-014099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925014099/0001104659-25-014099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925014099/tm256733d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T19:37:56.493360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}